- Home
- ASG vs VNDA Comparison
ASG vs VNDA Comparison
Compare ASG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASG
- VNDA
- Stock Information
- Founded
- ASG 1986
- VNDA 2002
- Country
- ASG United States
- VNDA United States
- Employees
- ASG N/A
- VNDA N/A
- Industry
- ASG Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- ASG Finance
- VNDA Health Care
- Exchange
- ASG Nasdaq
- VNDA Nasdaq
- Market Cap
- ASG 327.2M
- VNDA 270.2M
- IPO Year
- ASG N/A
- VNDA 2006
- Fundamental
- Price
- ASG $5.72
- VNDA $4.73
- Analyst Decision
- ASG
- VNDA Buy
- Analyst Count
- ASG 0
- VNDA 1
- Target Price
- ASG N/A
- VNDA $13.00
- AVG Volume (30 Days)
- ASG 324.3K
- VNDA 671.2K
- Earning Date
- ASG 01-01-0001
- VNDA 11-06-2024
- Dividend Yield
- ASG 8.09%
- VNDA N/A
- EPS Growth
- ASG N/A
- VNDA N/A
- EPS
- ASG N/A
- VNDA N/A
- Revenue
- ASG N/A
- VNDA $182,022,000.00
- Revenue This Year
- ASG N/A
- VNDA $6.70
- Revenue Next Year
- ASG N/A
- VNDA $51.03
- P/E Ratio
- ASG N/A
- VNDA N/A
- Revenue Growth
- ASG N/A
- VNDA N/A
- 52 Week Low
- ASG $4.47
- VNDA $3.30
- 52 Week High
- ASG $5.71
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- ASG 64.98
- VNDA 48.57
- Support Level
- ASG $5.66
- VNDA $4.68
- Resistance Level
- ASG $5.65
- VNDA $4.98
- Average True Range (ATR)
- ASG 0.05
- VNDA 0.18
- MACD
- ASG 0.00
- VNDA 0.05
- Stochastic Oscillator
- ASG 85.71
- VNDA 40.00
About ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.